COMPANY OVERVIEW

Profectus is a clinical-stage vaccine development company bringing a fundamental new approach to designing preventive and therapeutic vaccines for infectious diseases and oncolytic vaccines for cancer immunotherapy by finely tuning immune response to the specific target.

---

LOCATION

Baltimore, MD, USA

Pearl River, NY, USA

---

THERAPEUTIC AREAS

Infectious Disease

Vaccines

---

WEBSITE

https://www.profectusbiosciences.com/

---

CAREER WEBSITE

https://www.profectusbiosciences.com/about/careers.html

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

May 27, 2018

CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine

Oct 2, 2017

Profectus BioSciences Awarded NIH Contract for up to $22.25 Million to Develop Multi-Component Vaccine for Ebola, Marburg, and Lassa Viruses

Feb 9, 2017

Western Equine Encephalitis - Pipeline Review, H2 2016 - Key Players are Akshaya Bio, Altravax, EpiVax, HandP Labs and Profectus BioSciences - Research and Markets

Jan 9, 2017

Profectus BioSciences Bivalent Vaccine Protects Animals from Infection and Death After Exposure to Chikungunya or Zika Virus

Jan 19, 2016

Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial

For More Press Releases

---